• Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23
Hamlet BioPharmaHamlet BioPharma
  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
Press enter to begin your search
Category

Press releases

Oct 20 2023
Love0

Professor Gabriela Godaly will present valuable insights into the pressing global issues of tuberculosis and antibiotic resistance at the 178th Nobel Symposium in Chemistry in Stellenbosch, South Africa. The title of the presentation is: “Novel treatment for pulmonary tuberculosis”.

By Hamlet Biopharma Press releases

Professor Gabriela Godaly is working with Hamlet BioPharma  to develop  a new therapeutic concept to combat tuberculosis through the use of a bactericidal peptide. The…

Read More
Oct 16 2023
Love0

Strong anti-tumor effects detected in Alpha1H treated patients, for a combination of clinical and molecular endpoints

By Hamlet Biopharma Press releases

Hamlet BioPharma, the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces the results for the investigational drug…

Read More
Oct 16 2023
Love0

Ändrad tid för investerarmöte i Hamlet BioPharma AB

By Hamlet Biopharma Press releases

För att underlätta för alla att delta i mötet med Hamlet BioPharma ändras mötestiden till torsdag den 19:e oktober, 2023, kl 12:00. LÄNK https://us06web.zoom.us/j/87314915620?pwd=N2RCvKLjaqBNLBSL4bazO2fB0xCswt.1 Meeting…

Read More
Oct 11 2023
Love0

Martin Erixon återinträder som VD

By Hamlet Biopharma Press releases

Styrelsen har idag utsett Martin Erixon till tillförordnad (tf) VD vilket innebär att Martin Erixon återinträder i sin VD roll. Han ersätter därvid Petter Segelman…

Read More
Oct 09 2023
Love0

Hamlet BioPharma håller digitalt investerarmöte

By Hamlet Biopharma Press releases

Med anledning av höstförkylning kan Catharina Svanborg inte medverka på Aktiedagen, Aktiespararna idag. Därför bjuder Hamlet BioPharma in till ett digitalt investerarmöte via Zoom tisdagen…

Read More
Oct 05 2023
Love0

Hamlet BioPharma will be presenting at Aktiedagen, Aktiespararna, on Monday, October 9th, in Lund at 12:10 CET

By Hamlet Biopharma Press releases

Hamlet BioPharma is inviting you to join a presentation at Aktiedagen, Aktiespararna, on Monday October 9th at 12.10 CET, Elite Hotel Ideon, Lund. The company´s…

Read More
Aug 11 2023
Love0

Kommuniké Från Extra Bolagsstämman i Hamlet Pharma AB

By Hamlet Biopharma Press releases

Pressmeddelande, Malmö 11 augusti 2023 Som tidigare meddelats har Bolagsverket registrerat fusionen mellan Hamlet Pharma och SelectImmune Pharma. Detta innebär att Hamlet Pharma och SelectImmune Pharma…

Read More
Previous 1 … 7 8 9

See all news →

Recent Posts

  • Hamlet BioPharma announces progress in Tuberculosis therapy June 17, 2025
  • Hamlet BioPharma invites to investor meeting on the 18th of June June 17, 2025
  • Q3 Interim Report January – March 2025 May 22, 2025
  • Hamlet BioPharma bjuder in till pressträff den 22 maj May 21, 2025
  • Vetenskapligt genombrott för Alpha1H:s verkningsmekanism i blåscancer May 19, 2025

hbp-logo

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet Biopharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive newsletters

© 2025 Hamlet BioPharma.

  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
  • Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23

Hamlet Pharma AB

BMC D10
Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00
info@hamletpharma.com

Swedish